BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, BioSante’s president & CEO, will present a corporate update at the Stifel Nicolaus Healthcare Conference and Rodman & Renshaw Global Investment Conferences. The presentation will provide an overview of BioSante, including an update on the LibiGel® (testosterone gel) Phase III clinical development program and a review of published results using BioSante’s GVAX Cancer Immunotherapies in combination with ipilimumab (Ipi; Yervoy; BMS).

Mr. Simes will present at the Stifel Nicolaus 2012 Healthcare Conference on Wednesday, September 5, 2012 at 11:30 am EDT in Boston. The conference will be held September 5-6, 2012 at The Four Seasons in Boston, MA. A webcast of the presentation will be available at

Mr. Simes will also present at the Rodman & Renshaw Global Investment Conference on Monday, September 10, 2012 at 2:00 pm EDT in New York City. The conference will be held September 10-11, 2012 at the Waldorf=Astoria Hotel in New York City. A webcast of the presentation will be available at

About BioSante Pharmaceuticals, Inc.

BioSante’s corporate strategy is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and its company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies. BioSante´s products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development. BioSante also is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA). BioSante´s other products include an FDA-approved testosterone gel for male hypogonadism, which is licensed to Teva Pharmaceuticals USA, Inc., and the Pill-Plus™, an oral contraceptive in Phase II clinical development by Pantarhei Bioscience B.V. BioSante´s first FDA-approved product, Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, is marketed in the U.S. by Jazz Pharmaceuticals, BioSante´s licensee. Additional information is available online at:

Copyright Business Wire 2010